Physician profile
William Patrick Strong
NPI 1033775226
$3,226.99
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $292 · 2023: $1,540 · 2024: $1,396.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,935.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,935.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $575.37 | 2022-2024 | Farxiga, Breztri, Lokelma |
| Novo Nordisk INC | $435.85 | 2022-2024 | Ozempic, Rybelsus, Tresiba |
| Pfizer INC. | $331.35 | 2023-2024 | |
| Abbvie INC. | $236.35 | 2023-2024 | Qulipta, Ubrelvy, Vraylar |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $222.36 | 2022-2024 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $216.88 | 2022-2024 | |
| Amgen INC. | $208.59 | 2022-2024 | Otezla, Repatha, Evenity |
| Janssen Pharmaceuticals, INC | $183.19 | 2022-2024 | Xarelto |
| Exact Sciences Corporation | $167.41 | 2023-2024 | Cologuard Collection Kit |
| Lilly USA, LLC | $121.68 | 2022-2024 | Jardiance, Reyvow, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $94.82 | 2023-2024 | Jardiance |
| Astellas Pharma US INC | $86.26 | 2024 | Veozah |
| Biohaven Pharmaceutical Holding Company LTD. | $76.40 | 2022 | |
| Glaxosmithkline, LLC. | $60.26 | 2024 | Trelegy Ellipta, Arexvy |
| Novartis Pharmaceuticals Corporation | $53.06 | 2023-2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $36.53 | 2024 | Inspire |
| Otsuka America Pharmaceutical, INC. | $33.70 | 2023 | Rexulti |
| Kyowa Kirin, INC. | $28.15 | 2024 | Crysvita |
| Novavax INC | $27.19 | 2023 | Novavax Covid-19 Vaccine, Adjuvanted |
| Teva Pharmaceuticals USA, INC. | $16.20 | 2023 | Austedo |
| Dexcom, INC. | $15.39 | 2024 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Strong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.